10x Genomics Inc (NASDAQ:TXG) shares, rose in value on Wednesday, November 20, with price down by -1.84% to the previous day’s close as strong demand from buyers drove the stock to $13.32.
Actively observing the price movement in the last trading, the stock closed the session at $13.57, falling within a range of $13.1638 and $13.8. The value of beta (5-year monthly) was 1.873. Referring to stock’s 52-week performance, its high was $57.90, and the low was $12.95. On the whole, TXG has fluctuated by -12.02% over the past month.
With the market capitalization of 10x Genomics Inc currently standing at about $1.61 billion, investors are eagerly awaiting this quarter’s results, scheduled for in December.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 599.35M, with a low estimate of 151.49M and a high estimate of 155.1M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 153.46M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TXG’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of TXG currently trading nearly -13.51% and -25.64% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.05, while the 7-day volatility ratio is showing 5.17% which for the 30-day chart, stands at 5.83%. Furthermore, 10x Genomics Inc (TXG)’s beta value is 1.83, and its average true range (ATR) is 0.95.
A comparison of 10x Genomics Inc (TXG) with its peers suggests the former has fared considerably weaker in the market. TXG showed an intraday change of -1.84% in last session, and over the past year, it shrunk by -69.32%%.
Data on historical trading for 10x Genomics Inc (NASDAQ:TXG) indicates that the trading volumes over the past 10 days have averaged 2.36 and over the past 3 months, they’ve averaged 1.87 million. According to company’s latest data on outstanding shares, there are 105.04 million shares outstanding.
Nearly 17.61% of 10x Genomics Inc’s shares belong to company insiders and institutional investors own 78.79% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 7.61 million shares as on 2024-10-31, resulting in a short ratio of 3.26. According to the data, the short interest in 10x Genomics Inc (TXG) stood at 823.00 of shares outstanding as of 2024-10-31; the number of short shares registered in 2024-09-30 reached 7.44 million. The stock has fallen by -76.20% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TXG stock heading into the next quarter.
